NASDAQ:TRIL - Trillium Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trillium Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.93 -0.06 (-1.50 %) (As of 03/31/2020 06:25 AM ET) Add Compare Today's Range$3.57Now: $3.93▼$4.1050-Day Range$2.60MA: $4.31▼$7.2252-Week Range$0.24Now: $3.93▼$7.97Volume1.41 million shsAverage Volume5.40 million shsMarket Capitalization$322.88 millionP/E RatioN/ADividend YieldN/ABeta2.27 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRIL Previous Symbol CUSIPN/A CIK1616212 Webhttp://www.trilliumtherapeutics.com/ Phone416-595-0627Debt Debt-to-Equity RatioN/A Current Ratio1.72 Quick Ratio1.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$120,000.00 Price / Sales2,690.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.86) per share Price / Book-4.57Profitability EPS (Most Recent Fiscal Year)($1.38) Net Income$-41,620,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-64.66%Miscellaneous EmployeesN/A Outstanding Shares82,158,000Market Cap$322.88 million Next Earnings Date5/11/2020 (Estimated) OptionableOptionable Receive TRIL News and Ratings via Email Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TRIL Rates by TradingView Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions How has Trillium Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has decreased by 24.3% and is now trading at $3.93. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Trillium Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trillium Therapeutics. When is Trillium Therapeutics' next earnings date? Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Trillium Therapeutics. How were Trillium Therapeutics' earnings last quarter? Trillium Therapeutics Inc (NASDAQ:TRIL) issued its quarterly earnings data on Friday, May, 11th. The biotechnology company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.13. View Trillium Therapeutics' earnings history. What price target have analysts set for TRIL? 2 brokerages have issued 12-month target prices for Trillium Therapeutics' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Trillium Therapeutics' stock price to reach $4.00 in the next year. This suggests a possible upside of 1.8% from the stock's current price. View analysts' price targets for Trillium Therapeutics. Has Trillium Therapeutics been receiving favorable news coverage? News coverage about TRIL stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Trillium Therapeutics earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutTrillium Therapeutics. Are investors shorting Trillium Therapeutics? Trillium Therapeutics saw a increase in short interest in March. As of March 13th, there was short interest totaling 3,990,100 shares, an increase of 425.8% from the February 27th total of 758,900 shares. Based on an average daily volume of 4,986,700 shares, the short-interest ratio is currently 0.8 days. Currently, 6.2% of the shares of the stock are sold short. View Trillium Therapeutics' Current Options Chain. Who are some of Trillium Therapeutics' key competitors? Some companies that are related to Trillium Therapeutics include Karyopharm Therapeutics (KPTI), Dicerna Pharmaceuticals (DRNA), Corcept Therapeutics (CORT), Tricida (TCDA), Innoviva (INVA), TG Therapeutics (TGTX), ZEALAND PHARMA/S (ZEAL), Ligand Pharmaceuticals (LGND), Madrigal Pharmaceuticals (MDGL), Zogenix (ZGNX), I-Mab (ARQT), Heron Therapeutics (HRTX), NextCure (NXTC), Esperion Therapeutics (ESPR) and Opko Health (OPK). What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), Energy Transfer LP Unit (ET), SCYNEXIS (SCYX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Rigel Pharmaceuticals (RIGL), Actinium Pharmaceuticals (ATNM), Karyopharm Therapeutics (KPTI) and T2 Biosystems (TTOO). Who are Trillium Therapeutics' key executives? Trillium Therapeutics' management team includes the following people: Dr. Bjorn Johan Niclas Stiernholm, Pres, CEO & DirectorMr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 54)Dr. Robert Uger, Chief Scientific OfficerDr. Penka Petrova, Chief Devel. OfficerDr. Yaping Shou, Chief Medical Officer What is Trillium Therapeutics' stock symbol? Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL." How do I buy shares of Trillium Therapeutics? Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Trillium Therapeutics' stock price today? One share of TRIL stock can currently be purchased for approximately $3.93. How big of a company is Trillium Therapeutics? Trillium Therapeutics has a market capitalization of $322.88 million and generates $120,000.00 in revenue each year. The biotechnology company earns $-41,620,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. View additional information about Trillium Therapeutics. What is Trillium Therapeutics' official website? The official website for Trillium Therapeutics is http://www.trilliumtherapeutics.com/. How can I contact Trillium Therapeutics? Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected] MarketBeat Community Rating for Trillium Therapeutics (NASDAQ TRIL)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 286 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 480MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TRIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: How do CD ladders protect against rising interest rates?
